 |
市場調查報告書
商品編碼
1628090
2025 - 2034 年水產養殖疫苗市場機會、成長動力、產業趨勢分析與預測Aquaculture Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
||||||
2024 年，全球水產養殖疫苗市場價值為 4.074 億美元，預計 2025 年至 2034 年複合年成長率為 8%。 全球海鮮需求的增加和永續水產養殖實踐的推動推動了這一成長。
為了滿足飲食需求而擴大養魚業，凸顯了疾病爆發等挑戰，這可能會嚴重影響獲利能力和生產力。疫苗接種已成為預防感染、減少對抗生素的依賴和最大程度減少損失的重要工具。各國政府和監管機構正在積極推動疫苗接種計劃，以提高魚類健康和福利，進一步推動市場成長。重組 DNA 和次單位疫苗等疫苗開發技術的進步正在提高疫苗的功效和安全性，支持市場擴張。此外，發展中地區對水產養殖基礎設施的投資不斷增加，也為疫苗製造商創造了新的機會。
水產養殖疫苗是用來預防和控制養殖水生物種疾病的生物製劑。這些疫苗可促進動物健康，提高生產效率，並透過減少抗生素使用來支持永續實踐。
| 市場範圍 | |
|---|---|
| 開始年份 | 2024年 |
| 預測年份 | 2025-2034 |
| 起始值 | 4.074 億美元 |
| 預測值 | 8.628 億美元 |
| 複合年成長率 | 8% |
市場依疫苗類型分為去活化疫苗、減毒活疫苗、次單位疫苗等。 2024年，去活化疫苗佔據最大的市場佔有率，價值3.026億美元。這些疫苗因其安全性、持久免疫力和成本效益而備受青睞。它們能夠在沒有環境風險的情況下保護魚類族群，這使其成為水產養殖疾病管理的重要組成部分。
依給藥途徑分，市面上有注射疫苗、浸泡疫苗、噴霧疫苗和口服疫苗。 2024年注射疫苗引領市場，佔60.8%的佔有率。它們在直接傳遞抗原以刺激免疫反應方面的有效性使其成為水產養殖中控制細菌和病毒性疾病的流行選擇。
根據應用情況，細菌疫苗領域在 2024 年佔據主導地位，預計到 2034 年將達到 4.304 億美元。
由於其商業重要性和易受疾病影響，鮭魚市場預計將以 8.1% 的複合年成長率成長。對魚蛋白的需求不斷成長和永續實踐進一步支持了疫苗的採用。
歐洲在水產養殖疫苗市場上處於領先地位，水產養殖業實力雄厚的國家做出了巨大貢獻。該地區對魚類健康和福祉的關注繼續推動對疫苗的需求。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 細菌和病毒感染的盛行率激增
- 提高全球水產養殖產量
- 新型水產養殖疫苗的開發與上市
- 水產養殖疫苗的採用率超過抗生素
- 產業陷阱與挑戰
- 疫苗核准嚴格監管政策
- 複雜的疫苗開發程序
- 成長動力
- 成長潛力分析
- 監管環境
- 管道分析
- 未來市場趨勢
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按疫苗類型，2021 - 2034 年
- 主要趨勢
- 去活化疫苗
- 減毒活疫苗
- 亞單位疫苗
- 其他疫苗類型
第 6 章：市場估計與預測：按管理途徑，2021 年至 2034 年
- 主要趨勢
- 注射疫苗
- 浸泡和噴淋
- 口服疫苗
第 7 章：市場估計與預測：按應用分類，2021 - 2034 年
- 主要趨勢
- 細菌
- 病毒性的
- 寄生
- 組合
第 8 章：市場估計與預測：按物種，2021 - 2034 年
- 主要趨勢
- 鮭魚
- 鱒魚
- 羅非魚
- 鱸魚
- 鯛魚
- 大菱鮃
- 鯉魚
- 其他物種
第 9 章：市場估計與預測：按地區分類，2021 - 2034 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 挪威
- 愛爾蘭
- 土耳其
- 丹麥
- 亞太地區
- 中國
- 印度
- 印尼
- 菲律賓
- 泰國
- 越南
- 澳洲
- 紐西蘭
- 拉丁美洲
- 巴西
- 墨西哥
- 智利
- 中東和非洲
- 伊朗
- 埃及
第 10 章：公司簡介
- CIBA
- HIPRA
- Kyoto Biken Laboratories
- Kemin Industries
- Kyoritsuseiyaku Corporation
- Merck Animal Health (Merck & Co.)
- Nisseiken
- Phibro Animal Health Corporation
- Tecnovax
- Virbac
- Veterquimica
- Vaxxinova International
- Zoetis
The Global Aquaculture Vaccines Market was valued at USD 407.4 million in 2024 and is projected to grow at a CAGR of 8% from 2025 to 2034. This growth is fueled by increasing seafood demand worldwide and the push for sustainable aquaculture practices.
The expansion of fish farming to meet dietary needs has highlighted challenges like disease outbreaks, which can significantly impact profitability and productivity. Vaccination has become an essential tool to prevent infections, reduce dependency on antibiotics, and minimize losses. Governments and regulatory bodies are actively promoting vaccination programs to enhance fish health and welfare, driving market growth further. Technological advancements in vaccine development, such as recombinant DNA and subunit vaccines, are improving vaccine efficacy and safety, supporting market expansion. Additionally, growing investments in aquaculture infrastructure in developing regions are creating new opportunities for vaccine manufacturers.
Aquaculture vaccines are biological formulations used to prevent and manage diseases in farmed aquatic species. These vaccines promote animal health, enhance production efficiency, and support sustainable practices by reducing antibiotic use.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $407.4 Million |
| Forecast Value | $862.8 Million |
| CAGR | 8% |
The market is segmented by vaccine type into inactivated, live attenuated, subunit, and others. In 2024, inactivated vaccines held the largest market share, valued at USD 302.6 million. These vaccines are highly preferred for their safety, long-lasting immunity, and cost-effectiveness. Their ability to protect fish populations without environmental risks has made them a critical component of aquaculture disease management.
By route of administration, the market includes injection, immersion, spray, and oral vaccines. Injection vaccines led the market in 2024, accounting for 60.8% of the share. Their effectiveness in directly delivering antigens to stimulate immune responses makes them a popular choice for controlling bacterial and viral diseases in aquaculture.
Based on application, the bacterial vaccine segment dominated in 2024 and is expected to reach USD 430.4 million by 2034. This growth is driven by the increasing prevalence of bacterial infections in farmed aquatic species and the development of advanced vaccines offering enhanced protection.
The salmon segment is projected to grow at a CAGR of 8.1%, driven by its commercial importance and vulnerability to diseases. Rising demand for fish protein and sustainable practices are further supporting vaccine adoption.
Europe leads the aquaculture vaccines market, with significant contributions from countries with strong aquaculture industries. The region's focus on fish health and welfare continues to drive demand for vaccines.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Surging prevalence of bacterial and viral infections
- 3.2.1.2 Increasing aquaculture production across the globe
- 3.2.1.3 Development and launch of new aquaculture vaccines
- 3.2.1.4 Rising adoption of aquaculture vaccines over antibiotics
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Stringent regulatory policies for vaccine approval
- 3.2.2.2 Complex vaccine development procedures
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Inactivated vaccine
- 5.3 Live attenuated vaccine
- 5.4 Subunit vaccine
- 5.5 Other vaccine types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Injection vaccines
- 6.3 Immersion and spray
- 6.4 Oral vaccines
Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Bacterial
- 7.3 Viral
- 7.4 Parasitic
- 7.5 Combined
Chapter 8 Market Estimates and Forecast, By Species, 2021 - 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Salmon
- 8.3 Trout
- 8.4 Tilapia
- 8.5 Seabass
- 8.6 Seabream
- 8.7 Turbot
- 8.8 Carp
- 8.9 Other species
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Norway
- 9.3.7 Ireland
- 9.3.8 Turkey
- 9.3.9 Denmark
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 India
- 9.4.3 Indonesia
- 9.4.4 Philippines
- 9.4.5 Thailand
- 9.4.6 Vietnam
- 9.4.7 Australia
- 9.4.8 New Zealand
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Chile
- 9.6 Middle East and Africa
- 9.6.1 Iran
- 9.6.2 Egypt
Chapter 10 Company Profiles
- 10.1 CIBA
- 10.2 HIPRA
- 10.3 Kyoto Biken Laboratories
- 10.4 Kemin Industries
- 10.5 Kyoritsuseiyaku Corporation
- 10.6 Merck Animal Health (Merck & Co.)
- 10.7 Nisseiken
- 10.8 Phibro Animal Health Corporation
- 10.9 Tecnovax
- 10.10 Virbac
- 10.11 Veterquimica
- 10.12 Vaxxinova International
- 10.13 Zoetis
